Iron Deficiency Anemia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Iron Deficiency Anemia - Pipeline Review, H2 2016

Iron Deficiency Anemia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Iron Deficiency Anemia - Pipeline Review, H2 2016
Published Jul 20, 2016
68 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Iron Deficiency Anemia - Pipeline Review, H2 2016, provides an overview of the Iron Deficiency Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
- The report reviews pipeline therapeutics for Iron Deficiency Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Iron Deficiency Anemia therapeutics and enlists all their major and minor projects
- The report assesses Iron Deficiency Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Iron Defi

  
Source:
Document ID
GMDHC8253IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Iron Deficiency Anemia Overview71
Therapeutics Development82
  Pipeline Products for Iron Deficiency Anemia Overview81
  Pipeline Products for Iron Deficiency Anemia Comparative Analysis91
Iron Deficiency Anemia Therapeutics under Development by Companies101
Iron Deficiency Anemia Therapeutics under Investigation by Universities/Institutes111
Iron Deficiency Anemia Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Iron Deficiency Anemia Products under Development by Companies151
Iron Deficiency Anemia Products under Investigation by Universities/Institutes161
Iron Deficiency Anemia Companies Involved in Therapeutics Development176
  Galenica Ltd.171
  Johnson &Johnson181
  Novartis AG191
  Panion &Bf Biotech Inc201
  Pieris Pharmaceuticals, Inc.211
  Rockwell Medical, Inc.221
Iron Deficiency Anemia Therapeutics Assessment239
  Assessment by Monotherapy Products231
  Assessment by Target242
  Assessment by Mechanism of Action262
  Assessment by Route of Administration282
  Assessment by Molecule Type302
Drug Profiles3224
  CSJ-137 Drug Profile321
  Drug to Repalce Iron for Iron Deficiency Anemia Drug Profile331
  ferric carboxymaltose Drug Profile342
  ferric citrate Drug Profile368
  ferric pyrophosphate citrate Drug Profile447
  JNJ-42905343 Drug Profile511
  NSC-8679 Drug Profile521
  Peptides to Activate Erythroferrone for Iron Deficiency Anemia Drug Profile531
  PRS-080 Drug Profile542
Iron Deficiency Anemia Dormant Projects561
Iron Deficiency Anemia Product Development Milestones5710
  Featured News &Press Releases571
    Apr 28, 2016: Rockwell Medical Announces Triferic Presentation "Overcoming Functional Iron Deficiency in Your Hemodialysis Patients" at the National Kidney Foundation (NKF) Spring Clinical Meeting in Boston571
    Mar 29, 2016: Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease572
    Mar 21, 2016: China FDA Accepts Rockwell Medical s Triferic Drug Submission for Commercialization in China591
    Feb 22, 2016: Rockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia601
    Jan 19, 2016: Rockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 - May 1, 2016 in Boston, MA601
    Dec 01, 2015: Rockwell Medical to Present at Oppenheimer 26th Annual Healthcare Conference611
    Nov 30, 2015: Rockwell Medical's Triferic Receives Permanent J-Code for Renal Drug Reimbursement611
    Oct 28, 2015: Rockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at American Society of Nephrology Meeting November 2015611
    Oct 06, 2015: Rockwell Medical Announces Four Triferic Posters Accepted for Presentation at American Society of Nephrology Clinical Meeting November 2015621
    Sep 09, 2015: Rockwell Medical Announces the U.S. Commercial Launch of Triferic621
    Aug 31, 2015: A meta-analysis on individual-patient data reports that Ferinject treatment of iron deficiency in patients with systolic chronic heart failure is associated with reduced rates of cardiovascular hospitalisations and cardiovascular deaths631
    Jul 15, 2015: Rockwell Medical Announces Triferic Phase 3 CRUISE Studies Published in Nephrology Dialysis Transplantation641
    Jul 13, 2015: Rockwell Medical Announces Triferic ESA-Sparing PRIME Study Published in Kidney International651
    May 12, 2015: Rockwell Medical Announces Triferic Clinical Data Selected for Four Presentations at the 52nd ERA-EDTA Congress May 28-31, 2015 in London, UK661
    May 05, 2015: Rockwell Medical to Present at Bank of America Merrill Lynch 2015 Health Care Conference661
Appendix672
  Methodology671
  Coverage671
  Secondary Research671
  Primary Research671
  Expert Panel Validation671
  Contact Us671
  Disclaimer681

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Iron Deficiency Anemia - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Iron-Deficiency-Anemia-Pipeline-Review-H2-2016-2088-16227>
  
APA:
Global Markets Direct - Market Research. (2016). Iron Deficiency Anemia - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Iron-Deficiency-Anemia-Pipeline-Review-H2-2016-2088-16227>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.